The Cognitive Cost of Anticholinergic Burden: Decreased Response to Cognitive Training in Schizophrenia
Objective: Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training...
Saved in:
| Published in | The American journal of psychiatry Vol. 166; no. 9; pp. 1055 - 1062 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Arlington, VA
American Psychiatric Association
01.09.2009
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0002-953X 1535-7228 1535-7228 |
| DOI | 10.1176/appi.ajp.2009.09010017 |
Cover
| Abstract | Objective:
Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia.
Method:
Fifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients.
Results:
Serum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity.
Conclusions:
Serum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia. |
|---|---|
| AbstractList | Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia.
Fifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients.
Serum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity.
Serum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia. Objective: Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia. Method: Fifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients. Results: Serum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity. Conclusions: Serum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia. Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia.OBJECTIVESchizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia.Fifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients.METHODFifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients.Serum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity.RESULTSSerum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity.Serum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia.CONCLUSIONSSerum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia. Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the relationship between serum anticholinergic activity and baseline cognitive performance and response to computerized cognitive training in outpatients with schizophrenia. Fifty-five patients were randomly assigned to either computerized cognitive training or a computer games control condition. A neurocognitive battery based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was performed at baseline and after the intervention. Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49 patients. Serum anticholinergic activity showed a significant negative correlation with baseline performance in verbal working memory and verbal learning and memory, accounting for 7% of the variance in these measures, independent of age, IQ, or symptom severity. Patients in the cognitive training condition (N=25) showed a significant gain in global cognition compared to those in the control condition, but this improvement was negatively correlated with anticholinergic burden. Serum anticholinergic activity uniquely accounted for 20% of the variance in global cognition change, independent of age, IQ, or symptom severity. Serum anticholinergic activity in schizophrenia patients shows a significant association with impaired performance in MATRICS-based measures of verbal working memory and verbal learning and memory and is significantly associated with a lowered response to an intensive course of computerized cognitive training. These findings underscore the cognitive cost of medications that carry a high anticholinergic burden. The findings also have implications for the design and evaluation of cognitive treatments for schizophrenia. |
| Author | Fisher, Melissa Vinogradov, Sophia Pollock, Bruce G. Holland, Christine Kirshner, Margaret A. Warm, Heather |
| Author_xml | – sequence: 1 givenname: Sophia surname: Vinogradov fullname: Vinogradov, Sophia – sequence: 2 givenname: Melissa surname: Fisher fullname: Fisher, Melissa – sequence: 3 givenname: Heather surname: Warm fullname: Warm, Heather – sequence: 4 givenname: Christine surname: Holland fullname: Holland, Christine – sequence: 5 givenname: Margaret A. surname: Kirshner fullname: Kirshner, Margaret A. – sequence: 6 givenname: Bruce G. surname: Pollock fullname: Pollock, Bruce G. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21922195$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19570929$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1rFDEUhoNU7Lb6F8og6N2u-dhJJiJCXT-hIOgK3oUzmTM7WWaTMZmp1F_vjLu2tTf1IiQhz3M4580JOfLBIyFnjC4YU_IFdJ1bwLZbcEr1gmrKKGXqAZmxXORzxXlxRGaUUj7Xufh-TE5S2o5XKhR_RI6ZzhXVXM_IZt1gtgob73p3OZ1Sn4U6O_e9s01once4cTZ7M8QK_cvsLdqIkLDKvmDqgk-Y9eGWv47gvPObzPnsq23cr9A1Eb2Dx-RhDW3CJ4f9lHx7_269-ji_-Pzh0-r8Yg650v18yZYCdVHURYl1CZTKignOLC9AV8hB8gqFzQtmgXIUUiMVBUNQlZZ1mZfilKh93cF3cPUT2tZ00e0gXhlGzRSdmaIzY3Rmis78jW40X-_Nbih3WFn0fYQbO4Az_75415hNuDRCiVxIMRZ4figQw48BU292LllsW_AYhmSkklwpKkfw6R1wG4box1gM53Qpl1RN7ZzdbudmisPXjcCzAwDJQltH8Nala44zzceVj5zcczaGlCLW_x_IqzuidT30Lkzju_Z-Xez1P-_XE95j_QYMuuJw |
| CODEN | AJPSAO |
| CitedBy_id | crossref_primary_10_1016_j_pscychresns_2018_08_017 crossref_primary_10_1007_s40265_018_0874_x crossref_primary_10_1016_j_pin_2016_09_002 crossref_primary_10_1111_j_1399_5618_2011_00931_x crossref_primary_10_1176_appi_ajp_20220649 crossref_primary_10_1016_j_schres_2016_08_021 crossref_primary_10_1111_pcn_12912 crossref_primary_10_1080_14737175_2017_1331128 crossref_primary_10_1176_appi_ajp_2015_14050673 crossref_primary_10_9740_mhc_2021_01_012 crossref_primary_10_1016_j_schres_2018_04_011 crossref_primary_10_1177_0269881111434623 crossref_primary_10_1038_s41398_020_0746_5 crossref_primary_10_1097_HRP_0000000000000012 crossref_primary_10_1016_j_ncl_2020_01_004 crossref_primary_10_1016_j_schres_2012_06_006 crossref_primary_10_1186_s13063_016_1275_7 crossref_primary_10_1017_S0033291717003774 crossref_primary_10_1080_14737175_2017_1371014 crossref_primary_10_1016_j_eurpsy_2017_12_007 crossref_primary_10_3389_fpsyt_2024_1395198 crossref_primary_10_3389_fpsyt_2021_779607 crossref_primary_10_4102_sajpsychiatry_v28i0_1791 crossref_primary_10_1093_schbul_sbt232 crossref_primary_10_1007_s40263_024_01078_z crossref_primary_10_1017_S003329172000286X crossref_primary_10_1016_j_neuropharm_2012_05_050 crossref_primary_10_1038_s41386_022_01451_w crossref_primary_10_1136_eb_2013_101612 crossref_primary_10_1038_s41398_023_02400_x crossref_primary_10_1007_s40266_023_01050_4 crossref_primary_10_1038_npp_2010_156 crossref_primary_10_1016_j_ajp_2019_10_013 crossref_primary_10_1016_j_cpha_2022_09_003 crossref_primary_10_1016_j_inpsyc_2024_100006 crossref_primary_10_1016_j_schres_2019_01_016 crossref_primary_10_1016_j_schres_2019_10_022 crossref_primary_10_1146_annurev_med_050911_161504 crossref_primary_10_1017_S1355617709991123 crossref_primary_10_1017_S1092852921000249 crossref_primary_10_3389_fpsyt_2024_1451832 crossref_primary_10_1016_j_schres_2014_04_037 crossref_primary_10_1097_JCP_0000000000000850 crossref_primary_10_1016_j_schres_2014_01_006 crossref_primary_10_3389_fpsyt_2017_00177 crossref_primary_10_9740_mhc_2022_10_282 crossref_primary_10_3389_fpsyt_2017_00215 crossref_primary_10_1007_s10597_017_0183_y crossref_primary_10_1016_j_psychres_2024_116126 crossref_primary_10_1371_journal_pone_0151084 crossref_primary_10_1016_j_schres_2022_03_014 crossref_primary_10_1017_S0033291717000939 crossref_primary_10_2217_ahe_13_14 crossref_primary_10_3390_brainsci12020129 crossref_primary_10_3390_brainsci14080791 crossref_primary_10_1080_14740338_2020_1698545 crossref_primary_10_1016_j_schres_2018_04_028 crossref_primary_10_1016_j_schres_2018_04_025 crossref_primary_10_1016_j_scog_2024_100317 crossref_primary_10_1017_S0033291720001403 crossref_primary_10_1016_j_neubiorev_2015_05_011 crossref_primary_10_1080_14737175_2019_1581609 crossref_primary_10_1017_S0033291721001239 crossref_primary_10_1186_s12888_023_04552_y crossref_primary_10_3389_fpsyt_2018_00713 crossref_primary_10_1016_j_schres_2021_11_051 crossref_primary_10_2174_1745017902117010031 crossref_primary_10_3109_13651501_2012_709865 crossref_primary_10_1016_j_yhbeh_2011_01_011 crossref_primary_10_1177_0269881110391123 crossref_primary_10_1038_s41537_022_00320_1 crossref_primary_10_3389_fphar_2018_01542 crossref_primary_10_1177_1529100616661983 crossref_primary_10_1016_j_schres_2018_07_025 crossref_primary_10_1016_j_psychres_2013_07_035 crossref_primary_10_1016_j_schres_2025_01_017 crossref_primary_10_1007_s00228_017_2406_0 crossref_primary_10_1016_j_euroneuro_2024_02_005 crossref_primary_10_1093_schbul_sbae108 crossref_primary_10_1016_j_schres_2019_03_006 crossref_primary_10_1017_S1355617712000343 crossref_primary_10_1016_j_biopsych_2009_02_017 crossref_primary_10_1007_BF03544667 crossref_primary_10_1016_j_psychres_2015_11_028 crossref_primary_10_1016_j_schres_2012_05_016 crossref_primary_10_2147_NDT_S393586 crossref_primary_10_1016_j_psychres_2017_05_033 crossref_primary_10_1017_S0033291716002154 crossref_primary_10_1016_j_jpsychires_2012_10_001 crossref_primary_10_1097_JCP_0000000000000790 crossref_primary_10_1017_S0033291722003610 crossref_primary_10_2217_pgs_2022_0070 crossref_primary_10_1016_j_jad_2019_03_047 crossref_primary_10_1186_s12888_016_0707_y crossref_primary_10_1007_s40120_018_0105_0 crossref_primary_10_1016_j_jagp_2021_03_002 crossref_primary_10_1016_S2215_0366_24_00100_7 crossref_primary_10_1093_schbul_sbq038 crossref_primary_10_1517_14740338_2016_1165664 crossref_primary_10_1016_j_ijpsycho_2019_06_003 crossref_primary_10_1001_jamapsychiatry_2024_1441 crossref_primary_10_1093_schbul_sbab102 crossref_primary_10_3389_fpsyg_2015_01048 crossref_primary_10_3389_fpsyt_2022_970210 crossref_primary_10_1016_j_schres_2012_03_018 crossref_primary_10_1016_j_psc_2012_06_008 crossref_primary_10_1517_14740338_2011_579899 crossref_primary_10_1093_schbul_sbaa093 crossref_primary_10_1155_2016_8213165 crossref_primary_10_1016_j_jpsychires_2012_06_015 crossref_primary_10_1016_j_neuropharm_2012_07_048 crossref_primary_10_1331_JAPhA_2013_12138 crossref_primary_10_1016_j_jad_2019_07_059 crossref_primary_10_1002_14651858_CD012844_pub2 crossref_primary_10_1016_j_pnpbp_2010_07_029 crossref_primary_10_1177_07067437231179161 crossref_primary_10_1192_j_eurpsy_2022_2315 crossref_primary_10_1016_S1353_8020_13_70028_2 crossref_primary_10_1177_0004867419864438 crossref_primary_10_1080_13651501_2020_1767788 crossref_primary_10_1016_j_schres_2016_01_019 crossref_primary_10_1176_appi_focus_20160014 crossref_primary_10_1080_08039488_2020_1771767 crossref_primary_10_1080_14737175_2018_1455504 crossref_primary_10_1016_j_jns_2017_11_019 crossref_primary_10_1177_0004867419853348 crossref_primary_10_1016_j_jpsychires_2018_11_027 crossref_primary_10_1016_j_psychres_2023_115215 crossref_primary_10_1007_s00115_014_4027_5 crossref_primary_10_1007_s40266_016_0362_5 crossref_primary_10_1097_01_pra_0000375714_93078_a8 crossref_primary_10_1016_j_psychres_2020_113285 crossref_primary_10_1016_j_jbtep_2016_07_004 crossref_primary_10_1016_S2215_0366_24_00314_6 crossref_primary_10_15369_sujms_27_251 crossref_primary_10_1016_j_psychres_2015_10_036 crossref_primary_10_1176_appi_ajp_2020_20081212 crossref_primary_10_1007_s00213_024_06716_4 crossref_primary_10_1021_acs_jmedchem_6b00544 crossref_primary_10_1176_appi_ajp_20240260 crossref_primary_10_1016_j_psychres_2016_01_020 crossref_primary_10_1017_S1355617717001369 crossref_primary_10_1016_j_neunet_2011_02_006 crossref_primary_10_1016_j_schres_2024_01_020 crossref_primary_10_1016_j_jagp_2016_08_001 crossref_primary_10_1016_j_scog_2019_100160 crossref_primary_10_1517_14740338_2012_683523 crossref_primary_10_1007_s00406_023_01731_6 crossref_primary_10_1016_j_jagp_2013_01_012 crossref_primary_10_1016_j_jns_2018_02_037 crossref_primary_10_1016_j_schres_2014_11_018 crossref_primary_10_1016_j_psychres_2023_115607 crossref_primary_10_1093_schizbullopen_sgae013 crossref_primary_10_1176_appi_ajp_2010_10060838 crossref_primary_10_1038_npp_2017_25 crossref_primary_10_1177_0269881112447988 |
| Cites_doi | 10.1038/nature06289 10.1016/0920-9964(90)90045-9 10.1093/schbul/sbl072 10.1016/j.schres.2006.07.011 10.1017/S1461145705005407 10.1001/archpsyc.1980.01780160063007 10.1176/appi.ajp.2009.08050757 10.1176/appi.ps.54.8.1129 10.1016/S0920-9964(00)00033-5 10.1016/j.neuroscience.2006.03.011 10.1037/0021-843X.98.4.367 10.1016/j.pbb.2005.04.010 10.1097/00019442-200506000-00013 10.1016/S0301-0511(00)00083-1 10.1111/j.1460-9568.1996.tb01616.x 10.1176/ajp.139.11.1460 10.1016/j.brainresrev.2004.08.006 10.1523/JNEUROSCI.22-05-01905.2002 10.1016/S0920-9964(03)00123-3 10.1007/s00213-002-1170-7 10.1176/appi.ajp.161.1.116 10.1101/lm.70904 10.1176/ajp.155.8.1110 10.1523/JNEUROSCI.4104-07.2007 10.1212/01.wnl.0000183152.16690.26 10.1093/schbul/sbl019 10.1001/archpsyc.60.2.198 10.1016/j.schres.2004.01.009 10.1016/S0022-3956(02)00085-7 10.1126/science.279.5357.1714 10.1016/j.schres.2008.06.010 10.1093/schbul/13.2.261 10.1176/ajp.143.2.230 |
| ContentType | Journal Article |
| Copyright | 2009 INIST-CNRS Copyright American Psychiatric Association Sep 2009 |
| Copyright_xml | – notice: 2009 INIST-CNRS – notice: Copyright American Psychiatric Association Sep 2009 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM ADTOC UNPAY |
| DOI | 10.1176/appi.ajp.2009.09010017 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-7228 |
| EndPage | 1062 |
| ExternalDocumentID | oai:pubmedcentral.nih.gov:3735363 PMC3735363 1852634301 19570929 21922195 10_1176_appi_ajp_2009_09010017 10.1176/appi.ajp.2009.09010017 |
| Genre | Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIMH NIH HHS grantid: R01 MH068725 – fundername: NIMH NIH HHS grantid: R01 MH068725-01A1 – fundername: NCRR NIH HHS grantid: UL1 RR024131 – fundername: National Institute of Mental Health : NIMH grantid: R01 MH068725 || MH |
| GroupedDBID | --- --Z -DZ -~X .55 .GJ 08P 0WA 1CY 1HT 1KJ 1QT 23M 2QL 2WC 354 3O- 4.4 41~ 53G 5GY 5RE 6J9 6TJ 7K8 85S 8F7 8R4 8R5 AAAHA AAIKC AAJMC AAJWC AAKAS AAMNW AAQQT AAWTL AAWTO AAYJJ ABIVO ABPPZ ABZEH ACBMB ACGFO ACGOD ACHQT ACNCT ADBBV ADCOW ADZCM AENEX AERZD AETEA AFAZI AFFDN AFFNX AFMIJ AFOSN AGHSJ AGNAY AHJKT AHMBA AI. AIZTS ALMA_UNASSIGNED_HOLDINGS ASUFR BAJDF BAWUL BCR BENPR BKOMP BLC CS3 DIK E3Z EBS EJD EX3 F20 F5P F8P FA8 FJW G0H G8K GOZPB GRPMH HF~ HZ~ J5H L7B LPU LXL LXN MVM N4W N9A NEJ NHB OHT OK1 OVD P-O P2P PEA PQQKQ Q.- Q2X RAY RWL RXW RYA S10 SJN SKT TAE TEORI TR2 TWZ UBC UHB UKR ULE UPT UQL VH1 VVN WH7 WHG WOQ WOW X4V X6Y X7M XJT XOL XSW XZL YCJ YFH YOC YQI YQJ YRY YSK YWH YXB YYQ YZZ ZCA ZGI ZHY ZKB ZRR ZXP ZY1 ~A~ ~G0 ~X8 AAFWJ AAYXX ABDPE ADGHP ADMHG ADXHL CITATION H13 IQODW CGR CUY CVF ECM EIF NPM VXZ YIF YIN Z5M ABUFD K9. NAPCQ 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-a579t-4143e988f8befba006d1321c28a9de2a62de3c581ca02e369e0381ea7d96fb5b3 |
| IEDL.DBID | UNPAY |
| ISSN | 0002-953X 1535-7228 |
| IngestDate | Sun Oct 26 03:39:54 EDT 2025 Thu Aug 21 18:06:55 EDT 2025 Fri Sep 05 06:19:40 EDT 2025 Mon Oct 06 17:56:06 EDT 2025 Wed Feb 19 01:48:37 EST 2025 Wed Apr 02 07:36:11 EDT 2025 Wed Oct 01 02:33:53 EDT 2025 Thu Apr 24 23:08:22 EDT 2025 Wed Jul 24 08:10:55 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Psychosis Schizophrenia Cognition Treatment Cognitive remediation |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a579t-4143e988f8befba006d1321c28a9de2a62de3c581ca02e369e0381ea7d96fb5b3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/3735363 |
| PMID | 19570929 |
| PQID | 220464077 |
| PQPubID | 40661 |
| PageCount | 8 |
| ParticipantIDs | unpaywall_primary_10_1176_appi_ajp_2009_09010017 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3735363 proquest_miscellaneous_67627706 proquest_journals_220464077 pubmed_primary_19570929 pascalfrancis_primary_21922195 crossref_primary_10_1176_appi_ajp_2009_09010017 crossref_citationtrail_10_1176_appi_ajp_2009_09010017 appi_journals_10_1176_appi_ajp_2009_09010017 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-09-01 |
| PublicationDateYYYYMMDD | 2009-09-01 |
| PublicationDate_xml | – month: 09 year: 2009 text: 2009-09-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Arlington, VA |
| PublicationPlace_xml | – name: Arlington, VA – name: United States – name: Washington |
| PublicationTitle | The American journal of psychiatry |
| PublicationTitleAlternate | Am J Psychiatry |
| PublicationYear | 2009 |
| Publisher | American Psychiatric Association |
| Publisher_xml | – name: American Psychiatric Association |
| References | p_27 p_28 p_29 p_23 p_26 p_20 p_21 p_22 Nuechterlein KH (p_24) 2006 p_16 p_17 p_2 p_18 p_1 p_19 p_4 p_12 p_34 p_3 p_13 p_35 p_6 p_14 p_5 p_15 p_8 p_7 p_9 Nebes RD (p_25) 1997; 33 p_30 p_31 p_10 p_32 p_11 p_33 2574202 - J Abnorm Psychol. 1989 Nov;98(4):367-80 12842163 - J Psychiatr Res. 2003 Mar-Apr;37(2):99-108 15329293 - Schizophr Res. 2004 Oct 1;70(2-3):147-73 15956274 - Am J Geriatr Psychiatry. 2005 Jun;13(6):535-8 12373421 - Psychopharmacology (Berl). 2002 Oct;164(1):71-81 9699704 - Am J Psychiatry. 1998 Aug;155(8):1110-2 11880520 - J Neurosci. 2002 Mar 1;22(5):1905-13 3946662 - Am J Psychiatry. 1986 Feb;143(2):230-2 12883141 - Psychiatr Serv. 2003 Aug;54(8):1129-35 8758961 - Eur J Neurosci. 1996 Jul;8(7):1535-44 18160652 - J Neurosci. 2007 Dec 26;27(52):14442-7 16901950 - Schizophr Bull. 2006 Oct;32 Suppl 1:S123-31 1980611 - Schizophr Res. 1990 Mar-Apr;3(2):127-9 9497289 - Science. 1998 Mar 13;279(5357):1714-8 14702259 - Am J Psychiatry. 2004 Jan;161(1):116-24 15099605 - Schizophr Res. 2004 Jun 1;68(2-3):225-33 3616518 - Schizophr Bull. 1987;13(2):261-76 15708630 - Brain Res Brain Res Rev. 2005 Feb;48(1):98-111 9493484 - Psychopharmacol Bull. 1997;33(4):715-20 11120426 - Schizophr Res. 2000 Dec 15;46(2-3):139-48 16626873 - Neuroscience. 2006 Jul 21;140(4):1277-87 19448187 - Am J Psychiatry. 2009 Jul;166(7):805-11 6102457 - Arch Gen Psychiatry. 1980 Mar;37(3):293-7 15877932 - Int J Neuropsychopharmacol. 2006 Apr;9(2):175-89 6127957 - Am J Psychiatry. 1982 Nov;139(11):1460-2 18004384 - Nature. 2007 Nov 15;450(7168):425-9 15936063 - Pharmacol Biochem Behav. 2005 Jul;81(3):575-84 18657398 - Schizophr Res. 2008 Oct;105(1-3):105-13 11240312 - Biol Psychol. 2001 Mar;56(1):1-22 16928430 - Schizophr Res. 2006 Dec;88(1-3):63-72 17255120 - Schizophr Bull. 2007 Sep;33(5):1247-56 14747520 - Learn Mem. 2004 Jan-Feb;11(1):78-86 16275844 - Neurology. 2005 Nov 8;65(9):1487-9 12578438 - Arch Gen Psychiatry. 2003 Feb;60(2):198-203 |
| References_xml | – ident: p_20 doi: 10.1038/nature06289 – ident: p_11 doi: 10.1016/0920-9964(90)90045-9 – ident: p_34 doi: 10.1093/schbul/sbl072 – ident: p_3 doi: 10.1016/j.schres.2006.07.011 – ident: p_16 doi: 10.1017/S1461145705005407 – ident: p_26 doi: 10.1001/archpsyc.1980.01780160063007 – ident: p_22 doi: 10.1176/appi.ajp.2009.08050757 – ident: p_32 doi: 10.1176/appi.ps.54.8.1129 – ident: p_35 doi: 10.1016/S0920-9964(00)00033-5 – ident: p_4 doi: 10.1016/j.neuroscience.2006.03.011 – ident: p_10 doi: 10.1037/0021-843X.98.4.367 – ident: p_21 doi: 10.1016/j.pbb.2005.04.010 – ident: p_28 doi: 10.1097/00019442-200506000-00013 – ident: p_5 doi: 10.1016/S0301-0511(00)00083-1 – ident: p_15 doi: 10.1111/j.1460-9568.1996.tb01616.x – ident: p_2 doi: 10.1176/ajp.139.11.1460 – ident: p_17 doi: 10.1016/j.brainresrev.2004.08.006 – ident: p_13 doi: 10.1523/JNEUROSCI.22-05-01905.2002 – ident: p_9 doi: 10.1016/S0920-9964(03)00123-3 – ident: p_14 doi: 10.1007/s00213-002-1170-7 – ident: p_8 doi: 10.1176/appi.ajp.161.1.116 – volume: 33 start-page: 715 year: 1997 ident: p_25 publication-title: Psychopharmacol Bull – ident: p_12 doi: 10.1101/lm.70904 – ident: p_27 doi: 10.1176/ajp.155.8.1110 – ident: p_19 doi: 10.1523/JNEUROSCI.4104-07.2007 – ident: p_29 doi: 10.1212/01.wnl.0000183152.16690.26 – ident: p_31 doi: 10.1093/schbul/sbl019 – volume-title: Green MF: MATRICS Consensus Cognitive Battery Manual year: 2006 ident: p_24 – ident: p_7 doi: 10.1001/archpsyc.60.2.198 – ident: p_33 doi: 10.1016/j.schres.2004.01.009 – ident: p_6 doi: 10.1016/S0022-3956(02)00085-7 – ident: p_18 doi: 10.1126/science.279.5357.1714 – ident: p_30 doi: 10.1016/j.schres.2008.06.010 – ident: p_23 doi: 10.1093/schbul/13.2.261 – ident: p_1 doi: 10.1176/ajp.143.2.230 – reference: 15877932 - Int J Neuropsychopharmacol. 2006 Apr;9(2):175-89 – reference: 18160652 - J Neurosci. 2007 Dec 26;27(52):14442-7 – reference: 15936063 - Pharmacol Biochem Behav. 2005 Jul;81(3):575-84 – reference: 18004384 - Nature. 2007 Nov 15;450(7168):425-9 – reference: 9699704 - Am J Psychiatry. 1998 Aug;155(8):1110-2 – reference: 2574202 - J Abnorm Psychol. 1989 Nov;98(4):367-80 – reference: 6127957 - Am J Psychiatry. 1982 Nov;139(11):1460-2 – reference: 15708630 - Brain Res Brain Res Rev. 2005 Feb;48(1):98-111 – reference: 15329293 - Schizophr Res. 2004 Oct 1;70(2-3):147-73 – reference: 18657398 - Schizophr Res. 2008 Oct;105(1-3):105-13 – reference: 15099605 - Schizophr Res. 2004 Jun 1;68(2-3):225-33 – reference: 16626873 - Neuroscience. 2006 Jul 21;140(4):1277-87 – reference: 9493484 - Psychopharmacol Bull. 1997;33(4):715-20 – reference: 9497289 - Science. 1998 Mar 13;279(5357):1714-8 – reference: 17255120 - Schizophr Bull. 2007 Sep;33(5):1247-56 – reference: 11120426 - Schizophr Res. 2000 Dec 15;46(2-3):139-48 – reference: 12373421 - Psychopharmacology (Berl). 2002 Oct;164(1):71-81 – reference: 12842163 - J Psychiatr Res. 2003 Mar-Apr;37(2):99-108 – reference: 3616518 - Schizophr Bull. 1987;13(2):261-76 – reference: 16275844 - Neurology. 2005 Nov 8;65(9):1487-9 – reference: 3946662 - Am J Psychiatry. 1986 Feb;143(2):230-2 – reference: 14702259 - Am J Psychiatry. 2004 Jan;161(1):116-24 – reference: 8758961 - Eur J Neurosci. 1996 Jul;8(7):1535-44 – reference: 14747520 - Learn Mem. 2004 Jan-Feb;11(1):78-86 – reference: 11240312 - Biol Psychol. 2001 Mar;56(1):1-22 – reference: 6102457 - Arch Gen Psychiatry. 1980 Mar;37(3):293-7 – reference: 16928430 - Schizophr Res. 2006 Dec;88(1-3):63-72 – reference: 19448187 - Am J Psychiatry. 2009 Jul;166(7):805-11 – reference: 15956274 - Am J Geriatr Psychiatry. 2005 Jun;13(6):535-8 – reference: 12578438 - Arch Gen Psychiatry. 2003 Feb;60(2):198-203 – reference: 1980611 - Schizophr Res. 1990 Mar-Apr;3(2):127-9 – reference: 11880520 - J Neurosci. 2002 Mar 1;22(5):1905-13 – reference: 12883141 - Psychiatr Serv. 2003 Aug;54(8):1129-35 – reference: 16901950 - Schizophr Bull. 2006 Oct;32 Suppl 1:S123-31 |
| SSID | ssj0000372 |
| Score | 2.4124334 |
| Snippet | Objective:
Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors... Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition. The authors examined the... |
| SourceID | unpaywall pubmedcentral proquest pubmed pascalfrancis crossref appi |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1055 |
| SubjectTerms | Adult Adult and adolescent clinical studies Animals Atropine - blood Biological and medical sciences Cholinergic Antagonists - adverse effects Cholinergic Antagonists - blood Cholinergic Antagonists - therapeutic use Cognition & reasoning Cognition Disorders - blood Cognition Disorders - chemically induced Cognition Disorders - diagnosis Cognitive Therapy - methods Computer & video games Female Games, Experimental Health facilities Humans Information processing Intervention Male Medical sciences Middle Aged Neuronal Plasticity Neuropsychological Tests - statistics & numerical data Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Radioligand Assay Rats Rats, Sprague-Dawley Schizophrenia Schizophrenia - blood Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Severity of Illness Index Software Therapy, Computer-Assisted - methods Treatment Outcome |
| Title | The Cognitive Cost of Anticholinergic Burden: Decreased Response to Cognitive Training in Schizophrenia |
| URI | http://dx.doi.org/10.1176/appi.ajp.2009.09010017 https://www.ncbi.nlm.nih.gov/pubmed/19570929 https://www.proquest.com/docview/220464077 https://www.proquest.com/docview/67627706 https://pubmed.ncbi.nlm.nih.gov/PMC3735363 https://www.ncbi.nlm.nih.gov/pmc/articles/3735363 |
| UnpaywallVersion | submittedVersion |
| Volume | 166 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1535-7228 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0000372 issn: 0002-953X databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTgIkxPdHGBQ_8EhSJ67tmLdqMA3QJjRWqTxFTuJAoUurJRWCv55z4mQtII09RIrinBLHv8vd6X6-A3gZhxnNpOG-4lz6Y62oVSnl84JHmrIcrZwNFI-OxeF0_H7GZzsQdnthGtJ-ls6DcnEWlPOvDbdydZaNOp7YiEnGmWDXYFdwdL8HsDs9_jj53Lm5irNZWyPVtmmNYrcrOJTCpoTngf7WVam0xARqG5UN7MCWXbq10hV-oqLtbfEv5_NvDuWNdbnSP3_oxWLDQB3cgZNuai0v5XuwrtMg-_VH1ccrzf0u3HbuKpm0Q_dgx5T34fqRS8g_gC8IM7LfUZDwrKrJsiCT0u7nsv2AzDn-Wkm7WeI1edM4qZXJyUnLzTWkXm7In7qGFWRekk-bdMCHMD14e7p_6LveDb7mUtX-GP0wo-K4iFNTpBp1O8e4N8yiWKvcRFpEuWEZR6hoGhkmlLEpS6NlrkSR8pQ9gkG5LM0TIIUyOgy1ymxl-ThnWpiQpzzEB-XjglEPXtkFTJzyVUkT10iRNFdxvW2rTZV06-0B7xY6yVwddNuOY3Gp3KiXW7WVQC6VGG7hqBdDKxHhwT3Y64B18fZRZLPNVKL4i34Udd4mcnRplusqEWjBpKTCg8ctCC9eSHFJ0eP1QG7Bs7_BVhPfHkGgNVXFHbY8oD2Q_3OeT68usgc327ScJes9g0F9vjbP0bur0yHGNe8-DJ1W_wanpk0y |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTgIkNL4hDIYfeCSpE9d2zFu1MU1Im9BYpfIUOYkDhc6tllTT-Os552stII09RIpyOSWOf5c7636-A3gXhxnNpOG-4lz6I62oMynl84JHmrIcvZxbKB6fiKPJ6NOUT7cg7PbC1KT9LJ0Fdn4e2Nn3mlu5PM-GHU9syCTjTLA7sC04ht8D2J6cfB5_7cJcxdm0qZHq2rRGcbsrOJTCpYRngf7RVal0xATqGpUNnGDDLz1Y6hI_UdH0tvhX8Pk3h_Leyi711aWez9cc1OFDOO2G1vBSfgarKg2yX39UfbzV2B_BThuuknEjegxbxj6Bu8dtQv4pfEOYkf2OgoRnZUUWBRlbt5_L9QMyF_hrJc1miQ_koA5SS5OT04aba0i1WNM_axtWkJklX9bpgM9gcvjxbP_Ib3s3-JpLVfkjjMOMiuMiTk2RarTtHNe9YRbFWuUm0iLKDcs4QkXTyDChjEtZGi1zJYqUp-w5DOzCmpdACmV0GGqVucrycc60MCFPeYgPykcFox68dxOYtMZXJvW6Roqkvorz7VptqqSbbw94N9FJ1tZBd-045jfqDXu9ZVMJ5EaNvQ0c9WroJSI8uAe7HbCu3z6KXLaZSlR_20vR5l0iR1uzWJWJQA8mJRUevGhAeP1CikuKEa8HcgOe_Q2umvimBIFWVxVvseUB7YH8n-N8dXuVXbjfpOUcWe81DKqLlXmD0V2V7rX2_BveIUw5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+cognitive+cost+of+anticholinergic+burden%3A+decreased+response+to+cognitive+training+in+schizophrenia&rft.jtitle=The+American+journal+of+psychiatry&rft.au=Vinogradov%2C+Sophia&rft.au=Fisher%2C+Melissa&rft.au=Warm%2C+Heather&rft.au=Holland%2C+Christine&rft.date=2009-09-01&rft.issn=1535-7228&rft.eissn=1535-7228&rft.volume=166&rft.issue=9&rft.spage=1055&rft_id=info:doi/10.1176%2Fappi.ajp.2009.09010017&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-953X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-953X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-953X&client=summon |